Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57.2M
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
25.8M
-
Shares change
-
+25.8M
-
Total reported value, excl. options
-
$755M
-
Value change
-
+$755M
-
Number of buys
-
42
-
Price
-
$29.90
Significant Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q1 2021
43 filings reported holding DSGN - Design Therapeutics, Inc. - Common Stock as of Q1 2021.
Design Therapeutics, Inc. - Common Stock (DSGN) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.8M shares
of 57.2M outstanding shares and own 45.07% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (5.11M shares), Logos Global Management LP (2.73M shares), CITADEL ADVISORS LLC (2.53M shares), RA CAPITAL MANAGEMENT, L.P. (2.19M shares), Avoro Capital Advisors LLC (1.47M shares), BAKER BROS. ADVISORS LP (1.44M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.44M shares), JANUS HENDERSON GROUP PLC (1.19M shares), WELLINGTON MANAGEMENT GROUP LLP (1.14M shares), and EcoR1 Capital, LLC (1.14M shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.